All Peptides

Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and drives clinically significant weight loss of 10–15% body weight in 68-week trials.

Semaglutide 10mg — the most popular vial size for sustained GLP-1 dosing protocols. Provides 4–8 weeks of supply depending on dose escalation stage.

Semaglutide 15mg — the largest single vial for extended GLP-1 weight loss protocols. Covers 6–12 weeks of supply at maintenance doses and is the most cost-efficient per-mg option.

Cagrilintide (amylin analog) combined with Semaglutide (GLP-1 agonist) targets weight loss through two independent peptide pathways — additive effects vs. GLP-1 alone.

Tirzepatide is a dual GIP/GLP-1 receptor agonist that achieved 20.9% average weight loss in Phase 3 trials — the greatest weight reduction of any peptide in clinical history.

Tirzepatide 30mg — two months of supply at 15mg/week maintenance dose. Best single-vial value for extended tirzepatide protocols.

Four vials of Tirzepatide 15mg (60mg total) at the best per-vial price. Covers a complete 12–16 week protocol from dose escalation through maintenance.

Five vials of Tirzepatide 20mg (100mg total) — the largest supply bundle for high-dose extended protocols. Best economics for full 24-week protocol coverage.

Ten vials of Tirzepatide 15mg (150mg total) — institutional-scale supply for large extended protocols, multi-subject studies, or long-duration protocols.

Retatrutide is a triple GIP/GLP-1/Glucagon receptor agonist that showed 24.2% average weight loss in Phase 2 trials — potentially the most powerful anti-obesity peptide ever studied.

Retatrutide 15mg — larger supply vial for extended triple GIP/GLP-1/Glucagon protocols. Best per-mg economics for retatrutide protocols beyond the starter phase.